ClinicalTrials.gg
CompletedNCT05900986Updated May 20, 2026

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

A Phase 1/2 interventional study of LS301-IT 0.025 mg/kg and LS301-IT 0.05 mg/kg in Breast Cancer, DCIS and Invasive Duct Carcinoma of Breast, sponsored by Integro Theranostics. Completed at 9 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Primary conditionCarcinoma, Intraductal, NoninfiltratingRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Intraductal, Noninfiltrating
Why
  1. The study's listed conditions name Carcinoma, Intraductal, Noninfiltrating, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Integro Theranostics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Enrollment
131st of 171
22 · median 51
Started
2023
with 5 others
Phase 1/2
7 of 210
none open now
Registered
189th of 210
by date

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 131st largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2023, is one of 7 in phase 1/2, and was the 189th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) injection in female patients undergoing partial mastectomy for DCIS (whether or not undergoing planned SLNB) or Stage I-II primary invasive breast cancer undergoing SLNB. Safety is the primary objective of this study, followed by efficacy that will be assessed from fluorescence imaging observations and data.

Read the detailed description

This is a Phase 1b/Phase 2, open-label study to investigate the use of LS301-IT (investigational medicinal product [IMP]), a fluorescence imaging agent used for visualization of tumor margins and SLNs in female patients with DCIS or Stage I-II, primary invasive carcinoma of the breast, for which the patient's primary surgical treatment is partial mastectomy.

Eligible patients will be enrolled into either:

  • Phase 1b (Period 1): dose finding (escalation/de-escalation), and dose timing adjustment;
  • Phase 2a (Period 2): expanded sample size based on acceptable dosing regimen, that being the dose level(s) and time interval between LS301-IT injection and surgery, determined in Period 1; or
  • Period 2b (Period 3): allow surgeon to make additional surgical decisions based on fluorescence imaging findings during surgery (Period 3 will not be opened until results are available from Periods 1 and 2 and further FDA consultation is obtained).
03

Conditions studied

  • Breast Cancer
  • DCIS
  • Invasive Duct Carcinoma of Breast
04

In context

Carcinoma, Intraductal, Noninfiltrating Reclassified

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

This study's enrollment of 22 is below the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

Integro Theranostics is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • DCIS (whether or not undergoing planned SLNB) or patients with Stage I-II, primary invasive carcinoma of the breast undergoing SLNB for which the patient's primary surgical treatment is single breast partial mastectomy.
  • performance status of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • for surgery.
  • Simultaneous bilateral lumpectomies and bilateral partial mastectomies.
  • History of drug-related anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study
  • Prior chemotherapy, endocrine therapy, or biologic therapy for current clinically or proven breast cancer for Period 1.
  • Open surgery in the ipsilateral breast within a period of 1 year before administration of LS301-IT.
  • History of radiation therapy to the chest.
  • The lymphatic imaging agent ICG cannot be used prior to the partial mastectomy and SLNB procedures on the day of surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    LS301-IT

    LS301-IT will be administered by IV injection

    Drug: LS301-IT 0.025 mg/kg · Drug: LS301-IT 0.05 mg/kg · Drug: LS301-IT 0.075 mg/kg · Drug: LS301-IT 0.1 mg/kg

Interventions

  • DrugLS301-IT 0.025 mg/kg

    Drug page: Cronexitide lanocianine

    The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

  • DrugLS301-IT 0.05 mg/kg

    Drug page: Cronexitide lanocianine

    Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

  • DrugLS301-IT 0.075 mg/kg

    Drug page: Cronexitide lanocianine

    Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

  • DrugLS301-IT 0.1 mg/kg

    Drug page: Cronexitide lanocianine

    Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

07

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of participants with treatment-related adverse events

    Time frame: 30 days

  2. Pharmacodynamics

    Tumor to non-tumor ratio fluorescence response

    Time frame: during surgery

  3. Pharmacodynamics

    Surgeon's assessment using a semi-quantitative scoring system of fluorescence compared with intraoperative and postoperative pathology assessments.

    Time frame: During surgery

  4. Cmax

    maximum observed plasma concentration main metabolite in plasma.

    Time frame: 24 hours

  5. AUCinf

    area under the plasma concentration time curve from time 0 extrapolated to infinite time

    Time frame: 24 hours

  6. AUClast

    area under the plasma concentration-time curve from time 0 to the last quantifiable plasma concentration

    Time frame: 24 hours

  7. Tmax

    time to reach maximal plasma concentration (Tmax)

    Time frame: 24 hours

  8. t1/2

    elimination/apparent terminal elimination half life

    Time frame: 24 hours

08

Study locations

9 sites
  • Integro Theranostics Research Site #2
    Scottsdale, Arizona 85260, United States
  • Integro Theranostics Research Site #12
    Washington D.C., District of Columbia 20059, United States
  • Integro Theranostics Research Site #9
    Weston, Florida 33331, United States
  • Integro Theranostics Research Site #6
    The Bronx, New York 10461, United States
  • Integro Theranostics Clinical Research Site #8
    Winston-Salem, North Carolina 27103, United States
  • Integro Theranostics Research Site #10
    Cleveland, Ohio 44195, United States
  • Integro Theranostics Research Site #5
    Philadelphia, Pennsylvania 19107, United States
  • Integro Theranostics Research Site #3
    Dallas, Texas 75290, United States
  • Integro Theronostics Research Site #1
    Houston, Texas 77030, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Oct 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
Jun 13, 2023
StartActual
Jul 14, 2023
Primary completionActual
Oct 6, 2025
CompletionActual
May 6, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05900986
Lead sponsor
Integro Theranostics
Responsible party
Sponsor
First posted
Jun 13, 2023
Start date
Jul 14, 2023
Primary completion
Oct 6, 2025
Completion
May 6, 2026
Last update
May 20, 2026

Study contacts

Dan Thompson
study director · Integro Theranostics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cronexitide lanocianine

Start the discussion